Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829269 | 0.98 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL5828933 | 0.98 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL4223348 | 0.83 | USP2 (0.47) | MEN1KMT2AALDH1A1L3MBTL1ABCB1 | |
| SCHEMBL485946 | 0.81 | ANPEP (0.42) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL27768607 | 0.81 | MEN1 (0.38) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL5828931 | 0.81 | MEN1 (0.38) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL5829266 | 0.81 | MEN1 (0.38) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL31758131 | 0.78 | MEN1 (0.45) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL9231379 | 0.77 | HSD17B10 (0.37) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL2959602 | 0.77 | KMT2A (0.43) | MEN1KMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | MEN1 1928/4885KMT2A 1255/4885ALDH1A1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.